

Impact Analysis of SARS-CoV2 on Signaling Pathways during COVID19 Pathogenesis using Codon Usage Assisted Host-Viral Protein Interactions

Jayanta Kumar Das^a, Subhadip Chakraborty^b, Swarup Roy^{c,*},

^a*Department of Pediatrics, Johns Hopkins University School of Medicine, Maryland, USA*

^b*Department of Botany, Nabadwip Vidyasagar College, Nabadwip, India*

^c*Network Reconstruction & Analysis (NetRA) Lab, Department of Computer Applications, Sikkim University, Gangtok, India*

Abstract

Understanding the molecular mechanism of COVID19 disease pathogenesis helps in the rapid development of therapeutic targets. Usually, viral protein targets host proteins in an organized fashion. The pathogen may target cell signaling pathways to disrupt the pathway genes' regular activities, resulting in disease. Understanding the interaction mechanism of viral and host proteins involved in different signaling pathways may help decipher the attacking mechanism on the signal transmission during diseases, followed by discovering appropriate therapeutic solutions.

The expression of any viral gene depends mostly on the host translational machinery. Recent studies report the great significance of codon usage biases in establishing host-viral protein-protein interactions (PPI). Exploiting the codon usage patterns between a pair of co-evolved host and viral proteins may present novel insight into the host-viral protein interactomes during disease pathogenesis. Leveraging the codon usage pattern similarity (and dissimilarity), we propose a computational scheme to recreate the host-viral protein interaction network (HVPPI). We use seventeen (17) essential signaling pathways for our current work and study the possible targeting mechanism of SARS-CoV2 viral proteins on such pathway proteins. We in-

*Corresponding Author

Email addresses: jdass4@jhmi.edu (Jayanta Kumar Das),
subhadipiicb@gmail.com (Subhadip Chakraborty), sroy01@cus.ac.in (Swarup Roy)

fer both negatively and positively interacting edges in the network. We can find a relationship where one host protein may target by more than one viral protein.

Extensive analysis performed to understand the network topologically and the attacking behavior of the viral proteins. Our study reveals that viral proteins, mostly utilize codons, rare in the targeted host proteins (negatively correlated interaction). Among non-structural proteins, NSP3 and structural protein, Spike (S) protein, are the most influential proteins in interacting multiple host proteins. In ranking the most affected pathways, MAPK pathways observe to be worst affected during the COVID-19 disease. A good number of targeted proteins are highly central in host protein interaction networks. Proteins participating in multiple pathways are also highly connected in their own PPI and mostly targeted by multiple viral proteins.

Keywords: Protein Interaction Network, Codon usage bias, Bipartite graph, Cell signaling, Relative Synonymous Codon Usage, Centrality

1 Introduction

The entire world is passing through an unprecedented pandemic situation due to a massive outbreak of Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV2) infected viral disease, COVID-19. SARS-CoV2, is a large enveloped coronavirus (family -*Coronaviridae*, subfamily- *Coronavirinae*) with non-segmented, single-stranded, and positive-sense RNA genomes [1], transmits rapidly through human to human contacts. The need for the hour and utmost crucial for the scientific community to understand the disease pathogenesis of SAR-CoV2 in genomics and proteomics level for the rapid development of effective drugs or vaccines to control the COVID-19. Many recent works use HVPPI as an input to elucidate potential drug targets or repurposed drug molecules [2, 3, 4]. Host-pathogen protein interactions provide important insights into the molecular mechanisms of pathogenicity [5].

The host defense mechanism activates signal transduction molecules that initiate signals that activate immune effector mechanisms to protect the host from any pathogenic infections. Studies show that viral immune modulators perturb the human PPI network by targeting signaling pathways [6] to suppress the immunity in mammalian hosts [7]. To understand the molecular mechanism of pathogenicity of SARS-CoV2 during COVID19 disease, inves-

21 tigate the host-viral protein interactions is important. Knowledge gained
22 through the understanding of the viral proteins interact with the host pro-
23 teins involved in signaling pathways may translate into effective therapies
24 and vaccines. We aim to study the attacking pattern of SARS-CoV2 to-
25 wards its host proteins involved in signaling pathways. We focus on reg-
26 ulatory signaling pathways, mainly involved in signaling transduction and
27 cellular interactions. Signal transduction focuses on molecular and func-
28 tional aspects of viral interactions with host cell signaling with relevance
29 for the anti-viral response, the viral life cycle, viral pathogenesis, and cell
30 transformation [8]. Collectively, we consider total seventeen (17) major sig-
31 naling pathways namely *TGF-beta*, *Jak-STAT*, *PI3K-Akt*, *MAPK*, *HIF-1*,
32 *TNF*, *NF-kappa B*, *Cytokine-cytokine receptor interaction*, *Apoptosis*, *Th17*
33 *cell differentiation*, *Chemokine*, *Toll-like receptor*, *RIG-like receptor*, *IL-17*,
34 *Insulin Signaling*, *mTOR*, and *Adipocytokine* signaling pathways [9, 10, 11].

35 Using a high throughput experimental techniques, like yeast two-hybrid
36 (Y2H) screening and tandem-affinity purification coupled with mass spec-
37 trometry revealed miniatures the interactomes of a few model organisms so
38 far. Finding physical interactions is always not feasible due to the expensive
39 experimental setup. Most importantly, it is time-consuming. Experimental
40 methods are prone to incompleteness and noise. Because of the need for rapid
41 development of drugs or vaccines in current pandemic scenarios, the best al-
42 ternative is to guess the possible physical interactions computationally based
43 on available data sources. Considering different properties of proteins such as
44 sequence homology, gene co-expression, and phylogenetic profiles [12, 13, 14],
45 pairwise similarity is computed between a pair of proteins to predict a pos-
46 sible interaction between them. In addition to non-structural information,
47 structural data about a pair of proteins appears to be more effective in im-
48 proving prediction accuracy [15, 16, 3]. A number of *in-silico* approaches
49 recently attempted [2, 17] to reconstruct CoV2-Host PPI. Computational
50 methods for predicting interactions among protein molecules, *in-silico* de-
51 pend largely on the merit of the data in hand and similarity measures [18]
52 used. In reality, predicting deterministically whether two given proteins are
53 physically interacting or not based on the similarity of different structural
54 and non-structural features, is a challenging task due to the above crucial
55 factors.

56 Few studies report the great significance of codon usage biases [19, 20] in
57 establishing host-viral protein interactions [21]. Viral gene depends largely
58 on the host translational machinery for their expression. Consequently, vi-

59 ral proteins are co-evolved with host proteins and adopt mechanisms to ex-
60 ploit host codon usage biases. Interestingly, highly expressed viral proteins
61 are typically showing similar codon usage biases [22, 23] to target host pro-
62 teins [24]. On the other hand, to minimize the host immune system responses,
63 certain viral proteins adopt a mechanism to reduce viral protein expression.
64 Few works hypothesized [25, 26] that viral proteins enrich in codons that are
65 rare in their host genomes, and this rare codon usage helps in controlling the
66 expression level.

67 In this work, we try to infer a host-viral protein interaction network
68 leveraging the inherent correlation between codon usage biases between viral
69 and host proteins. To the best of our knowledge, no prior work exploiting
70 the codon usage pattern to infer host-viral PPI. We try to capture both
71 positive and negative interactions in the host-viral PPI. We use host proteins
72 involved in different human cellular signaling pathways by looking into their
73 significance in disease pathogenesis. Topologically and biologically, we try
74 to establish the relevance of the host proteins and highlight a few essential
75 proteins in the network, which may be useful drug targets for certain reported
76 drugs.

77 2. Methods and Materials

78 In this section, we discuss our proposed scheme for constructing a host-
79 viral PPI network using codon usage patterns of host and viral proteins.
80 To analyze the interaction mechanism of SARS-CoV2 viral proteins in host
81 signaling pathways, we select a set of all the genes involved in few candidate
82 signaling pathways.

83 2.1. Data acquisition and processing

84 Structurally, SARS-CoV2 consists of three categories of proteins, Struc-
85 tural, Nonstructural, and Accessory proteins. We select four (04) struc-
86 tural proteins, sixteen (16) non-structural proteins, and six (06) as reported
87 in Wuhan, China [27]. The details of the viral proteins are listed in Ta-
88 ble 1 (NCBI accession numbers for SERS-CoV2 proteins: MN908947.3, NC_-
89 045512).

90 To collect significant host genes involved in our candidate 17 signaling
91 pathways, we search Kyoto Encyclopedia of Genes and Genomes (KEGG)

Table 1: SARS-CoV2 Proteins considered for host-viral PPI

Protein category	Count	Protein Name
Structural	4	Spike (S), Envelope (E), Membrane (M), Nucleocapsid (N)
Non Structural	16	Nsp1-Nsp16
Accessory	6	Orf3a, Orf6, Orf7a, Orf7b, Orf8, Orf10

92 database ¹ for the genes involved in those pathways [28]. We observe a total
 93 of 2600 genes involved in the above pathways (Supplementary-A). Out of
 94 which, we select 1313 unique genes fully engaged in those signaling pathways
 95 as a good number of genes (1274) involve in more than one pathway. We
 96 summarize our target pathways and the number of genes involved, in the
 97 Table 2.

Table 2: Host proteins collected from different signaling pathways

Pathways	#Genes involved	Pathways	#Genes involved
NF-kappa B signaling pathway	105	Th17 cell differentiationl	108
Cytokine-cytokine receptor interaction	295	TGF-beta signaling pathway	95
TNF signaling pathway	113	Toll-like receptor signaling pathway	105
IL-17 signaling pathway	95	HIF-1 signaling pathway	110
RIG-I-like receptor signaling pathway	70	Apoptosis	137
MAPK signaling pathway	295	Insulin signaling pathway	138
Chemokine signaling pathway	190	mTOR signaling pathway	156
PI3K-Akt signaling pathway	355	Adipocytokine signaling pathway	70
Jak-STAT signaling pathway	163		

98 2.2. Computing Relative Synonymous Codon Usage (RSCU)

99 The genetic code describes how the 64-nucleotide triplets specify only
 100 twenty (20) different translated amino acids. These alternative codons for
 101 the same amino acids are termed as *synonymous codons*. However, most of
 102 the amino acids have at least two synonymous codons that are not used at the
 103 same frequencies in different genomes. According to the genome hypothesis
 104 proposed by Grantham et al. [29], the pattern of codon usage is species-
 105 specific and some way unique. Interestingly, even in the same genome, the
 106 codon usage varies significantly among genes with different expression lev-
 107 els [23], functions [30], and tissue-specific patterns [31]. Codon usage vari-

¹www.genome.jp/kegg/pathway.html

108 ation occurs may be due to natural selection and/or mutation pressure for
109 accurate and efficient translation in various organisms [19, 20]. Differences in
110 the frequency of occurrence on synonymous codons in coding DNA is termed
111 as synonymous codon usage bias [32].

112 RSCU is one the indices for measuring codon bias independent of the
113 amino acid composition and widely used to estimate the codon usage bias
114 [33, 34, 35]. It may use to quantify the similarity between any two gene
115 sequences by applying any classical proximity measure between a pair of
116 RSCU vectors. The similarity between RSCU vectors may reflect the possible
117 interactions between a couple of proteins in the PPI [35, 36, 34].


RSCU is the ratio between the observed number of occurrences of codons
and expected during uniform usage of synonymous codons and can be calcu-
lated as follows.

$$RSCU_{i,j} = \frac{X_{i,j}}{\frac{1}{n_i} \sum_{j=1}^{n_i} X_{i,j}}, \quad (1)$$


118 where, $X_{i,j}$ is the number of occurrences of the j^{th} codon for the i^{th} amino
119 acid, which is encoded by n_i synonymous codons. The RSCU score of a codon
120 more than 1.0 indicates excess usage (biased) of the codon, and less than 1.0
121 marks poor usage of that particular codon.

122 We report codon usage distribution of 59 codons across 26 SARS-CoV2
123 proteins in Figure 1 (a) and 1313 host proteins (Figure 1 (b)) involved in our
124 candidate signaling pathways. We observe that GGT, AGA, GCT, CCT,
125 GTT, TCT, ACA, CTT, TTA, ACT are the highly used (median RSCU
126 score ≥ 1.5 for each codon) codons in SAR-CoV2 proteins. On the other
127 hand, CGA, AGC, ACC, CGG, CTG, CCG, ACG, GCG, TCG, GGG rarely
128 used codons. In the case of host proteins (from 17 signaling pathways),
129 codons such as CTG, GTG, ATC, GCC, CAG, ACC, AGC, GGC, CCC are
130 highly used (median RSCU score ≥ 1.5 for each codon). The distribution
131 margins of RSCU values of those codons are relatively wider (Figure 1 (b)).
132 However, CCG, GTT, CGT, GCG, TCG, CAA, CTA, ATA, GTA, TTA
133 rarely used codons in host proteins. It is worth mentioning that for SARS-
134 CoV2 proteins, highly used codons are ending with T or A and host proteins,
135 ending with G or C at the third position of the codons.

136 We generate a 59-dimensional RSCU feature vector for each coding pro-
137 tein. We consider the usage pattern of only 59 codons (out of 64 available
138 codons). We ignore 03 stop codons and uniquely coded codons ATG and
139 TGG coded for Met and Trp amino acids, respectively [37]. For RSCU cal-



(a)



(b)

Figure 1: Distribution of RSCU scores for 59 codons for different (a) SARS-CoV2 proteins (b) Host proteins.

140 culation, we use *CAI* package [38] available free at ². Using the feature

²<https://cai.readthedocs.io/en/latest/>

141 vectors, we try to draw the similarity between host and viral proteins to
142 form a network, as discussed next.

143 2.3. Inferring Host-Viral Protein Interaction Network

144 Protein-Protein Interactions (PPI) are usually studied computationally
145 from a graph-theoretic perspective [18]. Interactions among different organ-
146 isms, such as a host and its pathogen, are primarily driven by interactions
147 among the host proteins and pathogen proteins. These interactions can also
148 be represented as host-pathogen PPI. Host-pathogen PPI usually represented
149 as a *bipartite graph* where any given interacting pair of nodes (proteins) does
150 not belong to the same organism. This network essentially provides the
151 known interactions of host proteins with pathogen proteins. On the other
152 hand, the interactions may be guessed (or inferred) computationally based
153 on different attributes of the target protein pairs when physical interactions
154 are missing. The host-pathogen interaction network essentially represents a
155 snapshot of the infection mechanism in a host cell infected by pathogens.
156 The virus-host interactome is essential for understanding virulence factors
157 influencing SARS-CoV2 pathogenesis [39]. Recent studies reported the use
158 of SARS-CoV2 and host PPI networks to study the pathogenesis of SARS-
159 CoV2 and identifying repurposed drugs [17? , 3, 40].

160 We infer interaction between two proteins using codon usage similarity.
161 Two proteins are considered to be strongly coupled if there RSCU similarity
162 bearing particular statistical significance.


163 Given $\mathcal{R}_v = \{x_1, x_2, \dots, x_{m=59}\}$ and $\mathcal{R}_h = \{y_1, x_2, \dots, y_{m=59}\}$, RSCU
164 vectors of a pair of host and viral proteins respectively, proteins are strongly
165 connected if p score is less than certain threshold τ i.e. $p(\mathcal{R}_v, \mathcal{R}_h) < \tau$.

166 We use SciPy version 1.5.0 (*scipy.stats*)³ for calculating Pearson corre-
167 lation coefficient, which uses 2-tailed p -value for measuring significant rela-
168 tionships [41].


169 The presence of interaction between a viral protein Vp_i and a host pro-
170 tein Hp_i is dependent on a significant threshold (τ) obtained from the given
171 RSCU-feature vectors of the host protein and the viral protein. For strong
172 relationship we set $p < 0.001$ and $\tau < p$.

173 Inferring the network, we consider two (02) kinds of interaction, positive
174 and negative, between a host and viral protein. Positive interaction indicates

³<https://scipy.org>



(a)



(b)

Figure 2: An example is showing for the viral protein and host protein codon usage RSCU pattern. x-axis is showing 59 codons and y-axis is for respective RSCU value of each codon. (a) Viral protein Orf7a that showed positive correlation ($r = 0.58$) with host protein TANK. (b) Viral protein Spike (S) that showed negative correlation ($r = -0.73$) with host protein GDF15.

175 possible similar codon usage patterns and negative interactions signifying
176 possible rare codon usage by SARS-CoV2 proteins compared to its interacting
177 host proteins.

178 Given $\mathcal{R}_v = \{x_1, x_2, \dots, x_{m=59}\}$ and $\mathcal{R}_h = \{y_1, x_2, \dots, y_{m=59}\}$, RSCU
179 vectors of a pair of host and viral proteins, respectively, we use Pearson
180 Correlation (ρ) [42] to calculate signed edge as follows.

$$\rho(\mathcal{R}_v, \mathcal{R}_h) = \frac{\sum_{i=1}^m (x_i - \bar{\mathcal{R}}_v)(y_i - \bar{\mathcal{R}}_h)}{\sqrt{\sum_{i=1}^m (x_i - \bar{\mathcal{R}}_v)^2} \sqrt{\sum_{i=1}^m (y_i - \bar{\mathcal{R}}_h)^2}} \quad (2)$$

181 where, $x_i \in \mathcal{R}_v$ and $y_i \in \mathcal{R}_h$, $\bar{\mathcal{R}}_v$ and $\bar{\mathcal{R}}_h$ are the mean of the vectors \mathcal{R}_v
182 and \mathcal{R}_h respectively. We use SciPy version 1.5.0⁴ for computing ρ .

183 Given a set of viral proteins, $V = \{v_1, v_2, \dots, v_n\}$ and host proteins $H =$
184 $\{h_1, h_2, \dots, h_n\}$ we can create a bipartite graph in the form of adjacency ma-
185 trix using above ρ and p values as follows.

$$I_{(V_i, H_j)} = \begin{cases} +1, & \text{if } p(\mathcal{R}_{v_i}, \mathcal{R}_{h_j}) < \tau \text{ and } \rho(\mathcal{R}_{v_i}, \mathcal{R}_{h_j}) > 0 \\ -1, & \text{if } p(\mathcal{R}_{v_i}, \mathcal{R}_{h_j}) < \tau \text{ and } \rho(\mathcal{R}_{v_i}, \mathcal{R}_{h_j}) < 0 \\ 0, & \text{if } p(\mathcal{R}_{v_i}, \mathcal{R}_{h_j}) > \tau \end{cases} \quad (3)$$

186 Next, we investigate the interaction mechanism of SARS-CoV2 on human
187 signaling pathways during COVID19 disease pathogenesis.

188 3. Results and Discussion

189 We predict the host-viral interaction graph based on the Equation 3 in-
190 volving 26 viral proteins with 1326 host proteins participating in 17 different
191 signaling pathways. Out of 34138 (26×1313) maximum possible interactions,
192 our method infers 9412 ($\approx 36\%$) strong interactions where 859 distinct host
193 proteins ($\approx 66\%$) are connected to at least one viral protein. We fix $\tau = 0.001$
194 as significant p -value for inferring strong edge between two proteins. Inter-
195 estingly, our inferred network reveals that out of 859 host proteins, a total
196 of 779 proteins is targeted by more than one viral protein. A snapshot of
197 isolated networks with one (viral) to many (host) interactions is shown in
198 Figure 3 between viral and host proteins.

⁴<https://scipy.org>




Figure 3: Disconnected networks showing one viral node (yellow node) to many host nodes interacting positively (blue node) and negatively (green node). Among 20 viral proteins, 09 viral proteins (Nsp1, Nsp2, Nsp6, Nsp7, Nsp9, M, N, Orf3a and Orf7a) are interacting positively by unique (one-to-one) host protein and the 08 viral proteins (Nsp3, Nsp5, Nsp10, Nsp11, Nsp12, Nsp16, Orf8 and Orf10) are interacting negatively with unique host protein. Nsp13, Nsp14 and Nsp15 involve both types of interactions.

199 Recent similar researches on SARS-CoV2 host proteins interaction [2]
 200 produce only viral protein oriented star-like topology and unable to report

201 any host protein oriented multiple interactions. We report a list of such highly
 202 connected host proteins with the viral proteins (at least 15) in Table 3. Many
 203 (viral) to one (host) interactions are also reported as Supplementary material
 204 (Supplementary-B).

Table 3: List of highly interacting host proteins (Hp) targeted by least 15 viral proteins (Vp). The host proteins are ranked by interacting viral protein count and shown along with an average correlation value. The list of the first 20 host proteins positively interact and the next 20 host proteins negatively interact with viral proteins.

Sl. No.	Hp	Vp count	Avg. (ρ)	Viral protein list
1	COL4A5	21	0.62	Nsp1, Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
2	STAM2	21	0.63	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf6, Orf7a, Orf8
3	LIFR	21	0.64	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf6, Orf7a, Orf8
4	IFNAR1	20	0.59	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
5	PPM1B	20	0.61	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
6	RPS6KA6	20	0.62	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, N, Orf3a, Orf6, Orf7a, Orf8
7	SOS2	20	0.63	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
8	PKN2	20	0.66	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
9	IRAK4	20	0.69	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
10	IL13RA2	19	0.61	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
11	APAF1	19	0.61	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
12	CUL2	19	0.61	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
13	DNM1L	19	0.63	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
14	MIOS	19	0.64	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
15	BIRC2	19	0.65	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
16	RPS6KA3	19	0.68	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
17	PPP1R3A	19	0.70	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, N, Orf3a, Orf7a, Orf8
18	SGK3	18	0.61	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp8, Nsp9, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
19	PPP3CB	18	0.62	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, N, Orf3a, Orf7a, Orf8
20	HIF1A	18	0.62	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp8, Nsp9, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, N, Orf3a, Orf7a, Orf8
1	GDF15	19	-0.62	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, Orf3a, Orf6, Orf8
2	FGF4	19	-0.60	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, Orf3a, Orf6, Orf8
3	SHC2	19	-0.58	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, M, Orf3a, Orf6, Orf8
4	CEBPB	18	-0.59	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
5	IRS2	18	-0.59	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
6	JUN	18	-0.58	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf817
7	EFNA2	18	-0.58	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
8	LPAR5	18	-0.58	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
9	GDF7	18	-0.58	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
10	FZD1	18	-0.58	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf818
11	FZD9	18	-0.57	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8

Table 3 – continued from previous page

Sl. No.	Hp	Vp count	Avg. (ρ)	Viral protein list
12	PPP2R3B	18	-0.57	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
13	MAPK8IP2	18	-0.57	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
14	DDIT4	18	-0.57	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
15	NOG	18	-0.57	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
16	SMAD6	18	-0.57	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
17	WNT6	18	-0.57	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
18	GREM2	18	-0.57	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
19	BMP7	18	-0.56	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8
20	FZD8	18	-0.56	Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, Nsp13, Nsp14, Nsp15, Nsp16, S, Orf3a, Orf6, Orf8


205 3.1. Distribution of correlation scores

206 While inferring an edge we consider only the significant p score ($p = .001$)
 207 and use the sign derived from correlation (ρ) as a type of the interaction. Sta-
 208 tistically, it is also important to study the distribution of correlation values
 209 (both positive and negative) between pairs of proteins in terms of codon
 210 usage patterns. From the distribution plot given in Figure 4 reveals that
 211 codon usage pattern between a pair of host and viral proteins (edge corre-
 212 lation) are non randomly associated and showing a Gaussian [43, 44] like
 213 distributions (with $p = 1.13e - 42$ for positive and $p = 7.819e - 94$ for
 214 negative correlation distributions based on normality test performed using
 215 SciPy.stats.normaltest⁵). The negative correlation is varied in the range
 216 $[-.73, -4.18]$ which covered 6325 (67%) interactions, and a positive correla-
 217 tion is varied within $[4.18, 8.44]$ including 3087 (33%) interactions. Positive
 218 correlation exhibits a more wider range of values than the negative range.


219 We further look into the correlation value distribution of a viral protein
 220 interacting with its target proteins. We report the correlation value range
 221 (both positive and negative) for 26 viral proteins in Figure 4. We observe
 222 that while fixing the p score at a high significance level, correlation values
 223 also appear to be significant, and it is ranging from ± 0.05 and above. The
 224 majority of the viral proteins are correlated both positively and negatively
 225 with its targets except for a few in the inferred network. Orf10 and Nsp10
 226 are viral proteins that are interacting with their target negatively. Similarly,
 227 viral proteins like N, Nsp1 and Orf7b are interacting positively only.

228 Based on our correlation analysis, we may confirm that while a viral

⁵<https://scipy.org/>



(a) Distribution of correlation scores for both positive and negative edges



(b) Range of positive and negative correlations score a viral protein interacting with its target host proteins

Figure 4: (a) Frequency distribution of positive (right) and negative (left) correlation scores for interacting proteins in terms of RSCU based codon similarity showing a normal distribution. (b) Box plot showing the range of correlation values for each viral protein while associated with its target proteins.

229 protein targets its a host, it mimics similar codon usage as its target to
230 uphold the expression of target host proteins. Similarly, viral proteins use
231 a set of codons that are rarely used in their targets to down-regulate the
232 expression of its target. We observe that in the case of host proteins involved
233 in signaling pathways, the majority of SARS-CoV2 proteins aimed to break
234 down the normal pathways by downregulating the key proteins involved in
235 such pathways.


236 *3.2. Degree distribution of host and viral proteins*

237 In any interacting network, the node's degree conveys essential informa-
238 tion about the influence of the node within the network. In the case of host-
239 viral PPI, a high degree of viral protein may be a key protein that interacts
240 with a high number of host proteins. Pharmacologically, the identification
241 of such proteins may help design a small molecule that may bind with it to
242 inhibit its influence during disease pathogenesis. The same may be applica-
243 ble to host proteins. If host proteins have a high degree, it indicates that
244 the host proteins are targeted by more number of viral proteins. However,
245 it may require further investigation about its importance in its own network
246 i.e., host-host protein networks. If a host protein found to be significant
247 concerning its degree, suitable repurposed drug molecules may be identified
248 for the same.


249 While focusing on highly interacting viral proteins, interestingly, we ob-
250 serve that the maximum number of highly interacting proteins belongs to
251 the non-structural family. In the case of structural proteins, S is highly in-
252 teracting (more than 600) protein. Out of accessory proteins, Orf8 shows
253 maximum interaction count close to protein S.

254 We report the degree distribution for each of the viral proteins from our
255 network in Figure 5 (a). From the figure, we may observe that majority
256 of the viral proteins carrying a high node degree. Out of all the SARS-
257 CoV2 proteins, Nsp3 shows the maximum degree (≈ 700), which interacts
258 with more than 80% of the candidate host proteins involved in 17 different
259 signaling pathways. Concerning negative edges, i.e., connected, negatively,
260 Nsp3 is still on top, followed by Nsp16, Nsp13, and so on. While considering
261 positive edges S, Nsp6 and Orf7a are found to be highly interactive. Few
262 viral proteins like Nsp11, Orf7b, E, Nsp1, Orf10, and Nsp11 found to be less
263 interactive, comparatively.

264 We show the distribution of the degree of 859 host proteins in Figure 5 (b),
265 interacting with 26 viral proteins. From the distribution plot, we can observe



(a) Viral proteins and their total connections or degree (positive and negative edges) with host proteins.



(b) Degree distribution of host proteins interacting with viral proteins

Figure 5: (a) The bar chart showing for number of host protein count for each viral protein based on correlation analysis (p -value < 0.001). Pc-positive count, Nc-negative count; positive and negative count are based on positive and negative correlation respectively. (b) Degree distribution of 859 host proteins in terms of number of associated viral proteins (degree) count (x-axis) with host protein frequency (y-axis).

266 that majority (82) of the host proteins are connected with only one viral node.
267 While considering highly targeted proteins by multiple viral proteins, we see
268 fewer than 10 proteins with degree 21 (maximum degree), which is lowest
269 within the distribution. Even though our network is a bipartite graph, we
270 observe that the number of low-degree nodes is high and high degree nodes
271 are lowest in the graph. It further indicates that hub or central nodes are
272 relatively less, which is somehow following the scale-free properties [45] of a
273 complex network. However, with an exception to the power-law distribution
274 curve, we observe relatively good host nodes possessing a degree within the
275 range 11 to 18.

276 3.3. Ranking highly targeted signaling pathways and its impact on COVID19

277 To study the most effected pathways in our 17 candidate set of pathways,
278 we rank them based on the percentage of host protein targeted by any vi-
279 ral proteins out of total proteins involved in those pathways and report in
280 Figure 6.




Figure 6: Ranking of 17 candidate signaling pathways. The pathway ranking is done by observing the host protein percentage from pathways that interact with any of the SARS-CoV2 (26) proteins.

281 From the figure, it is observable that Mitogen-activated protein kinase

282 (MAPK) signaling pathways is viral proteins target profoundly affected path-
283 ways with more than 50% proteins from that pathway. MAPK proteins com-
284 municate signals from a receptor on the cell's surface to the DNA in the nu-
285 cleus of the cell, which is essential in a viral infection point of view. Besides,
286 MAPK proteins are involved in a series of vital signal transduction pathways
287 that regulate processes such as cell proliferation, cell differentiation, and cell
288 death in humans.

289 Beside MAPK, other ranked signaling pathways are significantly affected
290 during COVID19 infection. Under physiological conditions, adipokines act
291 mainly in adipose tissue (paracrine or autocrine) or circulate through the
292 blood circulation to distant target organs, regulating their growth and de-
293 velopment, metabolism and tissue remodeling. However, under pathological
294 conditions, the synthesis and secretion of adipokines are disordered, leading
295 to obesity, diabetes, heart disease, and other metabolic disorders. Our results
296 show that the adipocytokine pathway is affected during COVID19. It impli-
297 cates the patients with comorbid conditions like diabetes and heart disease
298 show worst disease aggression, which already observed in various reportings.
299 The mTOR pathway is a central regulator of mammalian metabolism and
300 physiology, with essential roles in the function of tissues, including liver, mus-
301 cle, white and brown adipose tissue, and the brain. It dysregulated in human
302 diseases, such as diabetes, obesity, depression, aging-related problems, and
303 certain cancers. Our result corroborates with the same, and it's reported
304 that aged patients are more prone to the infection due to the dysregulation
305 of m-TOR pathway or some other unknown reasons.

306 It also comes to notice that some COVID19 affected deaths are due to
307 multiple organ failure. HIF1 and RIG1 like receptor pathways, are involved in
308 normal immunoregulation and various organ functioning. Dysregulation may
309 cause immune compromisation and multiple organ failure through ischaemic
310 heart disease, acute lung injury, pulmonary hypertension, pulmonary fibro-
311 sis, chronic obstructive pulmonary disease (COPD), acute liver failure, liver
312 fibrosis and acute kidney injury etc. Our result also supports these findings.

313 In our ranking, the fourth most affected pathway is the TGF- β (Trans-
314 forming growth factor-beta), which is a multi-functional cytokine belong-
315 ing to the transforming growth factor superfamily that includes three differ-
316 ent mammalian isoforms (TGF- β 1 to 3, HGNC symbols TGFB1, TGFB2,
317 TGFB3) and many other signaling proteins. TGFB proteins are produced
318 by all-white blood cell lineages. This pathway activates different downstream
319 substrates and regulatory proteins, inducing transcription of various target

320 genes that function in differentiation, chemotaxis, proliferation, and activa-
321 tion of many immune cells.

322 3.4. Centrality analysis of host proteins

323 Studies on human host-viral protein interactions reveal that virus tending
324 to targeted attacks towards host proteins [46, 47, 48] by interacting with
325 important (central) host proteins. We consider a host protein important if
326 it interacts with many other host proteins in host-host protein networks.
327 We use BioGRID [49] to calculate the centrality score of our candidate host
328 proteins ⁶. We report top 100 central proteins in the Supplementary C. We
329 observe that a good number of interacting host proteins in our network are
330 highly central in the host PPI. We observe that a common set of viral proteins
331 targets central genes, and such proteins are involved in multiple pathways.
332 For instance, if we consider few top central proteins, MYC (2843), TRIM25
333 (2656), EGFR (2452), BRCA1 (2236), MDM2 (2219), NTRK1 (2030), KRAS
334 (1944), ELAVL1 (1914) and HSP90AA1 (1734), they are found to be targeted
335 commonly by the viral proteins such Nsp2, Nsp3, Nsp4, Nsp5, Nsp8, Nsp10,
336 Nsp12, Nsp13.

337 If we consider the participation of most central proteins in our candidate
338 pathways, we observe that PI3K-Akt signaling pathway (36) followed by the
339 MAPK signaling pathway (35) contains most of the central proteins. From
340 the disease pathogenesis perspective, a pathway may be more crucial if it
341 contains highly central proteins targeted by viral proteins. Moving one step
342 ahead, we may rank our 17 pathways based on the number of participat-
343 ing central proteins (top 100) in the above pathways and report it in the
344 Table 4. More details about the top 100 central host proteins are listed in
345 Supplementary C.

346 Interestingly, in terms of the number of targeted proteins and which are
347 also central in host-host PPI, the signaling pathway MAPK is one of the
348 worst affected pathways among 17 candidate pathways.

349 Prior researches also identified an exciting fact that viral proteins target
350 host proteins that are pathway central, i.e., participating in multiple path-
351 ways [48]. In addition to PPI centrality, we study the pathway centrality of
352 the host proteins regarding our 17 signaling pathways. Degree distribution
353 of host proteins in terms of their density of participation in 17 pathways

⁶<https://thebiogrid.org/>

Table 4: Participation count of central proteins in candidate pathways.

Signaling pathway	#Central Proteins
PI3K-Akt signaling pathway	36
MAPK signaling pathway	35
Apoptosis	27
NF-kappa B signaling pathway	24
TNF signaling pathway	24
IL-17 signaling pathway	20
RIG-I-like receptor signaling pathway	19
HIF-1 signaling pathway	19
Th17 cell differentiation	18
Toll-like receptor signaling pathway	18
Chemokine signaling pathway	17
TGF-beta signaling pathway	15
mTOR signaling pathway	14
Insulin signaling pathway	12
Adipocytokine signaling pathway	12
Jak-STAT signaling pathway	11
Cytokine-cytokine receptor interaction	3

354 is reported in Figure 7. We observe a nice power-law [45] like distribution
355 where the majority of proteins are participating in only one pathway and
356 fewer numbers are having high participation in multiple pathways. We list a
357 few top highly pathway central proteins and few interesting facts in Table 5.
358 The table shows that the pathway central proteins are also highly connected
359 in their own PPI and mostly targeted by multiple viral proteins.

360 **4. Conclusion**

361 In this work, we put a novel effort in recreating host-viral PPI using
362 the codon usage pattern similarity between coding DNA sequences of host
363 proteins that are participating in a few major signaling pathways and SARS-
364 CoV2 viral proteins. We inferred both positive and negative edges between
365 interacting proteins, which depict an important association between viral
366 and host proteins. We analyze our inferred network topologically concerning
367 degree distribution and node centrality. We observed interesting facts on
368 how viral proteins are targeting their host proteins.




Figure 7: Degree distribution of 859 interacting host proteins in terms of number of associated signaling pathways (candidate).

Table 5: Few top pathway central proteins with the number of pathways they participating (out of 17 pathways), PPI centrality score and number of viral proteins (Vp) targeting the proteins

Protein	#Pathway centrality	PPI centrality	#Interacting Vp count
IKBKB	13	552	2
CHUK	12	462	11
MAPK3	12	337	16
RELA	12	859	10
AKT1	11	886	11
AKT2	11	113	12
AKT3	11	61	15
IKBKG	11	959	9
TNF	11	497	11
MAPK8	9	444	12
MAPK9	9	260	15
NFKBIA	9	501	8
PIK3CA	9	190	19
PIK3CB	9	82	17
PIK3CD	9	28	17
PIK3R1	9	684	5
PIK3R2	9	190	16

369 We restricted our current study on a few significant signaling pathways.
 370 Our method is generic and useful to draw a more extensive network covering

371 all important pathways in the future.

372 **Supplementary Materials**

373 **Supplementary-A:** The pathway wise list of genes involving 17 signal-
374 ing pathways.

375 **Supplementary-B:** The host protein, each of which interacts with one
376 or more viral interacting proteins and their list.

377 **Supplementary-C:** The list of top score 100 central host protein. For
378 each protein, centrality score, correlation, interacting viral protein, and in-
379 volved pathways shown in different columns.

380 **References**

- 381 [1] D. Wrapp, N. Wang, K. S. Corbett, J. A. Goldsmith, C.-L. Hsieh,
382 O. Abiona, B. S. Graham, J. S. McLellan, Cryo-em structure of the
383 2019-ncov spike in the prefusion conformation, *Science* 367 (2020) 1260–
384 1263.
- 385 [2] D. E. Gordon, G. M. Jang, M. Bouhaddou, J. Xu, K. Obernier, K. M.
386 White, M. J. O’Meara, V. V. Rezelj, J. Z. Guo, D. L. Swaney, et al., A
387 sars-cov-2 protein interaction map reveals targets for drug repurposing,
388 *Nature* (2020) 1–13.
- 389 [3] Y. Zhou, Y. Hou, J. Shen, Y. Huang, W. Martin, F. Cheng, Network-
390 based drug repurposing for novel coronavirus 2019-ncov/sars-cov-2, *Cell*
391 *discovery* 6 (2020) 1–18.
- 392 [4] B. R. Beck, B. Shin, Y. Choi, S. Park, K. Kang, Predicting commercially
393 available antiviral drugs that may act on the novel coronavirus (sars-
394 cov-2) through a drug-target interaction deep learning model, *Compu-
395 tational and structural biotechnology journal* (2020).
- 396 [5] V. Memišević, N. Zavaljevski, S. V. Rajagopala, K. Kwon, R. Pieper,
397 D. DeShazer, J. Reifman, A. Wallqvist, Mining host-pathogen protein
398 interactions to characterize burkholderia mallei infectivity mechanisms,
399 *PLoS Comput Biol* 11 (2015) e1004088.

- 400 [6] A. Pichlmair, K. Kandasamy, G. Alvisi, O. Mulhern, R. Sacco, M. Hab-
401 jan, M. Binder, A. Stefanovic, C.-A. Eberle, A. Goncalves, et al., Viral
402 immune modulators perturb the human molecular network by common
403 and unique strategies, *Nature* 487 (2012) 486–490.
- 404 [7] R. Draenert, J. Frater, J. G. Prado, *Virus immune evasion: new mech-
405 anism and implications in disease outcome*, 2012.
- 406 [8] A. Kieser, Signal transduction by viral factors: critical interface between
407 the virus and its host cell with implications for the viral life cycle and
408 disease development, *Signal Transduction* 7 (2007) 3–4.
- 409 [9] M. A.-A.-K. Khan, A. B. Islam, Sars-cov-2 proteins exploit host’s ge-
410 netic and epigenetic mediators for the annexation of key host signaling
411 pathways that confers its immune evasion and disease pathophysiology,
412 *bioRxiv* (2020).
- 413 [10] L. Chen, H. Deng, H. Cui, J. Fang, Z. Zuo, J. Deng, Y. Li, X. Wang,
414 L. Zhao, Inflammatory responses and inflammation-associated diseases
415 in organs, *Oncotarget* 9 (2018) 7204.
- 416 [11] Z. Zhao, J. Xia, O. Tastan, I. Singh, M. Kshirsagar, J. Carbonell,
417 J. Klein-Seetharaman, Virus interactions with human signal transduc-
418 tion pathways, *International journal of computational biology and drug
419 design* 4 (2011) 83–105.
- 420 [12] O. Kuchaiev, M. Rašajski, D. J. Higham, N. Pržulj, Geometric de-
421 noising of protein-protein interaction networks, *PLoS computational
422 biology* 5 (2009) e1000454.
- 423 [13] Y. Murakami, K. Mizuguchi, Homology-based prediction of interac-
424 tions between proteins using averaged one-dependence estimators, *BMC
425 bioinformatics* 15 (2014) 213.
- 426 [14] L. Salwinski, D. Eisenberg, Computational methods of analysis of
427 protein–protein interactions, *Current opinion in structural biology* 13
428 (2003) 377–382.
- 429 [15] Q. C. Zhang, D. Petrey, L. Deng, L. Qiang, Y. Shi, C. A. Thu,
430 B. Bisikirska, C. Lefebvre, D. Accili, T. Hunter, et al., Structure-based

- 431 prediction of protein–protein interactions on a genome-wide scale, *Nature* 490 (2012) 556–560.
432
- 433 [16] R. Singh, D. Park, J. Xu, R. Hosur, B. Berger, Struct2net: a web
434 service to predict protein–protein interactions using a structure-based
435 approach, *Nucleic acids research* 38 (2010) W508–W515.
- 436 [17] F. Messina, E. Giombini, C. Agrati, F. Vairo, T. A. Bartoli, S. Al Mog-
437 hazi, M. Piacentini, F. Locatelli, G. Kobinger, M. Maeurer, et al., Covid-
438 19: viral–host interactome analyzed by network based-approach model
439 to study pathogenesis of sars-cov-2 infection, *Journal of Translational*
440 *Medicine* 18 (2020) 1–10.
- 441 [18] P. H. Guzzi, S. Roy, *Biological Network Analysis: Trends, Approaches,*
442 *Graph Theory, and Algorithms*, Academic Press, 2020.
- 443 [19] P. M. Sharp, L. R. Emery, K. Zeng, Forces that influence the evolution of
444 codon bias, *Philosophical Transactions of the Royal Society B: Biological*
445 *Sciences* 365 (2010) 1203–1212.
- 446 [20] G. M. Jenkins, E. C. Holmes, The extent of codon usage bias in human
447 rna viruses and its evolutionary origin, *Virus research* 92 (2003) 1–7.
- 448 [21] J. L. Chaney, P. L. Clark, Roles for synonymous codon usage in protein
449 biogenesis, *Annual review of biophysics* 44 (2015) 143–166.
- 450 [22] H. Song, H. Gao, J. Liu, P. Tian, Z. Nan, Comprehensive analysis of
451 correlations among codon usage bias, gene expression, and substitution
452 rate in *arachis duranensis* and *arachis ipaënsis* orthologs, *Scientific re-*
453 *ports* 7 (2017) 1–12.
- 454 [23] M. Dos Reis, L. Wernisch, R. Savva, Unexpected correlations between
455 gene expression and codon usage bias from microarray data for the whole
456 *escherichia coli* k-12 genome, *Nucleic acids research* 31 (2003) 6976–6985.
- 457 [24] I. Bahir, M. Fromer, Y. Prat, M. Linial, Viral adaptation to host: a
458 proteome-based analysis of codon usage and amino acid preferences,
459 *Molecular systems biology* 5 (2009) 311.
- 460 [25] S. Mueller, D. Papamichail, J. R. Coleman, S. Skiena, E. Wimmer,
461 Reduction of the rate of poliovirus protein synthesis through large-scale

- 462 codon deoptimization causes attenuation of viral virulence by lowering
463 specific infectivity, *Journal of virology* 80 (2006) 9687–9696.
- 464 [26] R. W. Tindle, Immune evasion in human papillomavirus-associated cer-
465 vical cancer, *Nature Reviews Cancer* 2 (2002) 59–64.
- 466 [27] F. Wu, S. Zhao, B. Yu, Y.-M. Chen, W. Wang, Z.-G. Song, Y. Hu, Z.-W.
467 Tao, J.-H. Tian, Y.-Y. Pei, et al., A new coronavirus associated with
468 human respiratory disease in china, *Nature* 579 (2020) 265–269.
- 469 [28] M. Kanehisa, Pathway databases and higher order function, *Advances*
470 *in Protein Chemistry* 54 (2000) 381–408.
- 471 [29] R. Grantham, C. Gautier, M. Gouy, R. Mercier, A. Pave, Codon catalog
472 usage and the genome hypothesis, *Nucleic acids research* 8 (1980) 197–
473 197.
- 474 [30] Y.-s. Liu, J.-h. Zhou, H.-t. Chen, L.-n. Ma, Z. Pejsak, Y.-z. Ding,
475 J. Zhang, The characteristics of the synonymous codon usage in en-
476 terovirus 71 virus and the effects of host on the virus in codon usage
477 pattern, *Infection, Genetics and Evolution* 11 (2011) 1168–1173.
- 478 [31] J. B. Plotkin, H. Robins, A. J. Levine, Tissue-specific codon usage and
479 the expression of human genes, *Proceedings of the National Academy*
480 *of Sciences* 101 (2004) 12588–12591.
- 481 [32] R. Khandia, S. Singhal, U. Kumar, A. Ansari, R. Tiwari, K. Dhama,
482 J. Das, A. Munjal, R. K. Singh, Analysis of nipah virus codon usage
483 and adaptation to hosts, *Frontiers in microbiology* 10 (2019) 886.
- 484 [33] P. M. Sharp, W.-H. Li, An evolutionary perspective on synonymous
485 codon usage in unicellular organisms, *Journal of molecular evolution* 24
486 (1986) 28–38.
- 487 [34] M. Dilucca, S. Forcelloni, G. Cimini, A. Giansanti, Co-evolution be-
488 tween codon usage and protein-protein interaction networks in bacterial
489 genomes, *bioRxiv* (2020).
- 490 [35] H. S. Najafabadi, R. Salavati, Sequence-based prediction of protein-
491 protein interactions by means of codon usage, *Genome biology* 9 (2008)
492 1–9.

- 493 [36] P. L. Meintjes, A. G. Rodrigo, Evolution of relative synonymous codon
494 usage in human immunodeficiency virus type-1, *Journal of bioinformat-*
495 *ics and computational biology* 3 (2005) 157–168.
- 496 [37] Y. Chen, Q. Xu, X. Yuan, X. Li, T. Zhu, Y. Ma, J.-L. Chen, Anal-
497 ysis of the codon usage pattern in middle east respiratory syndrome
498 coronavirus, *Oncotarget* 8 (2017) 110337.
- 499 [38] B. D. Lee, Python implementation of codon adaptation index, *Journal*
500 *of Open Source Software* 3 (2018) 905. URL: [https://doi.org/10.](https://doi.org/10.21105/joss.00905)
501 [21105/joss.00905](https://doi.org/10.21105/joss.00905). doi:10.21105/joss.00905.
- 502 [39] Q. Liang, J. Li, M. Guo, X. Tian, C. Liu, X. Wang, X. Yang, P. Wu,
503 Z. Xiao, Y. Qu, et al., Virus-host interactome and proteomic survey of
504 pmbcs from covid-19 patients reveal potential virulence factors influenc-
505 ing sars-cov-2 pathogenesis, *bioRxiv* (2020).
- 506 [40] P. H. Guzzi, D. Mercatelli, C. Ceraolo, F. M. Giorgi, Master regula-
507 tor analysis of the sars-cov-2/human interactome, *Journal of clinical*
508 *medicine* 9 (2020) 982.
- 509 [41] P. Sedgwick, Pearson’s correlation coefficient, *Bmj* 345 (2012) e4483.
- 510 [42] J. Benesty, J. Chen, Y. Huang, I. Cohen, Pearson correlation coefficient,
511 in: *Noise reduction in speech processing*, Springer, 2009, pp. 1–4.
- 512 [43] R. B. d’Agostino, An omnibus test of normality for moderate and large
513 size samples, *Biometrika* 58 (1971) 341–348.
- 514 [44] R. D’AGOSTINO, E. S. Pearson, Tests for departure from normality.
515 empirical results for the distributions of b^2 and b , *Biometrika* 60 (1973)
516 613–622.
- 517 [45] R. Albert, A.-L. Barabási, Statistical mechanics of complex networks,
518 *Reviews of modern physics* 74 (2002) 47.
- 519 [46] R. Albert, H. Jeong, A.-L. Barabási, Error and attack tolerance of
520 complex networks, *nature* 406 (2000) 378–382.

- 521 [47] V. Navratil, B. de Chasse, C. R. Combe, V. Lotteau, When the human
522 viral infectome and disease networks collide: towards a systems biol-
523 ogy platform for the aetiology of human diseases, *BMC systems biology*
524 5 (2011) 13.
- 525 [48] R. R. Halehalli, H. A. Nagarajaram, Molecular principles of human
526 virus protein–protein interactions, *Bioinformatics* 31 (2015) 1025–1033.
- 527 [49] C. Stark, B.-J. Breitkreutz, T. Reguly, L. Boucher, A. Breitkreutz,
528 M. Tyers, Biogrid: a general repository for interaction datasets, *Nucleic*
529 *acids research* 34 (2006) D535–D539.

530 **Author contributions**

531 J.K.D. and S.R. conceived and designed the study. J.K.D. performed
532 computational work, S.C. interpreted Biological validation. J.K.D. and S.R.
533 were in charge for overall direction, planning, and supervision. All authors
534 participate in planing, discussion and provided critical feedback. All authors
535 participate in writing original manuscript and approved.

536 **Competing interests**

537 The authors declare no competing interests.